Bimzelx beats Skyrizi in psoriatic arthritis, raising stakes for AbbVie

The rapid growth of AbbVie’s Skyrizi has put it within reach of Humira’s peak sales, but new data from UCB, announced Wednesday, stiffen the competition. 

In a head-to-head Phase III comparing Bimzelx bimekizumab-bkzx from UCB S.A. (Euronext:UCB) and Skyrizi risankizumab-rzaa from AbbVie Inc. (NYSE:ABBV) in adults with active psoriatic arthritis, Bimzelx proved superior on the primary endpoint of ACR50, the American College of Rheumatology’s response criteria for a 50% or greater improvement from baseline for patients in disease metrics such as joint pain and swelling, function, and inflammatory markers. ...